SMNROTCPharmaceutical PreparationsFiscal year ends December 31Also trades as SMNRW

Semnur Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$0.43+0.03 (+6.75%)

Close on Oct 19, 2026

Market cap: $98.30M
P/E (TTM): –
Dividend yield: –

Semnur Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31
Research & Development	1.25	1.27	0.71	1.14	0.50	0.19	0.24	0.23	–	–	–	–	–	–	–	–
General & Administrative	2.98	3.31	5.44	151	0.50	0.48	0.54	1.07	–	–	–	–	–	–	–	–
Operating Expenses	4.22	4.58	6.16	153	1.00	0.67	0.78	1.30	–	–	–	–	–	–	–	–
Operating Income	-4.22	-4.58	-6.16	-153	-1.00	-0.67	-0.78	-1.30	-0.17	-0.37	-0.56	–	–	–	–	–
Interest Expense	0.12	–	–	–	0	0.03	0.03	0.03	0.02	0.02	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	0.02	0.08	0.09	0.20	0.64	0.65	1.03	0.91	0.73	0.38	0.11	0
Other Non-Operating Income	-0.12	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–
Net Income	-4.35	-4.58	-6.16	-153	-1.00	-0.67	-0.17	-1.30	-1.11	-1.51	0.46	-1.01	-0.68	0.31	-0.03	-0.01
EPS (Basic)(per share)	-0.02	-0.02	-0.03	-0.76	-0.01	-0.01	0.00	-0.01	–	–	–	–	–	–	–	-0.01
EPS (Diluted)(per share)	-0.02	-0.02	-0.03	-0.76	-0.01	-0.01	0.00	-0.01	–	–	–	–	–	–	–	-0.01
Shares Outstanding (Basic, Weighted)(shares)	230	230	217	202	200	200	200	200	–	–	–	–	–	–	–	1.24
Shares Outstanding (Diluted, Weighted)(shares)	230	230	217	202	200	200	200	200	–	–	–	–	–	–	–	1.24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 505.0%

Financial strength

Current ratio: 0.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –